Stock BIO BIOTEST AG
Add to a list
To use this feature you must be a member
Log inSign up

All News Biotest AG Xetra

Equities

BIO

DE0005227201

Market Closed - Xetra
Other stock markets
 11:36:10 2024-07-12 am EDT 		5-day change 1st Jan Change
42 EUR +0.48% Intraday chart for Biotest AG -1.41% -1.41%
Jul. 01 Kedrion Biopharma Inc. Selects by Biotest to Distribute Its Immunoglobulin Yimmugo in the U.S. Following Recent FDA Approval CI
Jun. 17 Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary Immunodeficiencies CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Grifols Biotest to achieve USD 1 billion in US sales of Yimmugo over next seven years
AQ
Kedrion selected by Biotest to distribute its Immunoglobulin Yimmugo in the U.S.
AQ
Biotest prepares launch of its immunoglobulin Yimmugo in the USA, establishing a framework for a strategic billion-dollar distribution agreement with Kedrion
EQ
Kedrion Biopharma Inc. Selects by Biotest to Distribute Its Immunoglobulin Yimmugo in the U.S. Following Recent FDA Approval
CI
Biotest : Rules of Procedure of the Supervisory Board PDF, 184 KB
PU
Biotest's sustainability campaign GoFuture part of the new documentary 'Future Seeds'
EQ
Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary Immunodeficiencies
CI
Milestone for Biotest: US approval for innovative immunoglobulin Yimmugo
EQ
Biotest : Speech of Peter Janssen - German Version
PU
Ex-dividend day for final dividend
FA
Biotest AG: Annual General Meeting approves dividend distribution
EQ
Biotest Aktiengesellschaft Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024
EQ
Biotest Launches New Plasma Collection Center in Germany
MT
Biotest AG opens 12th plasma collection centre in Germany
EQ
Biotest AG increased sales by 32% in the financial year 2023
EQ
Biotest : Sustainability report Declaration of compliance 2023
PU
Biotest Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Biotest : Invitation / Agenda of Annual General Meeting 2024
PU
Biotest : Notes on agenda item 1 - German Version
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIO3 Stock
  4. BIO Stock
  5. News Biotest AG